Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Stop the ‘good’ vs ‘bad’ snap judgments and watch your world become more interesting - 2Creative Tech Contraptions That Will Work on Your Life
- 3Major Scottish gangland figure Steven Lyons arrested in Bali
- 4Newly discovered link between traumatic brain injury in children and epigenetic changes could help personalize treatment for recovering kids
- 5This Overlooked Predator Is Running Out of Time—Why Conservationists Are Racing to Save the Striped Hyena
- Move. Cheer. Dance. Do the wave. How to tap into the collective joy of 'we mode'
- Viable Correspondence: Building Solid Connections
- Why is the Artemis 2 rocket launch different from all other rocket launches?
- What will the Artemis 2 astronauts eat during their historic moon mission? (video)
- 4 Coolers for Present day Kitchens
- Bomb blast in packed Nigerian mosque kills five
- 7 Powerful Methods for forestalling Telephone Overheating: Keep Your Gadget Cool
- Israel intensifies Lebanon attacks and hits areas not in Hezbollah's control
- Thousands of genomes reveal the wild wolf genes in most dogs’ DNA
